Biogen's Alzheimer's drug aducanumab implodes in a PhIII disaster — putting them at a perilous crossroads
Biogen’s big late-stage play in Alzheimer’s has just crashed. And the damage will be extensive.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.